Biblio

Author [ Title(Desc)] Type Year
Filters: Author is Yang, Yi  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
C
Kong X, Guan J, Ma W, Li Y, Xing B, Yang Y, Wang Y, Gao J, Wei J, Yao Y, et al. CD34 Over-Expression is Associated With Gliomas' Higher WHO Grade. Medicine (Baltimore). 2016;95(7):e2830.
Li S, Zhang L, Zhou Q, Jiang S, Yang Y, Cao Y. Characterization of Stem Cells and Immune Cells in Preterm and Term Mother's Milk. J Hum Lact. 2019:890334419838986.
Yang Y, He L, Xie Y, Zhu L, Wu J, Fan Y, Yang Y, Sun X. correction of various β-thalassemia mutations in human hematopoietic stem cells. Front Cell Dev Biol. 2023;11:1276890.
Yang Y, Wang S, Cai J, Liang J, Zhang Y, Xie Y, Luo F, Tang J, Gao Y, Shen S, et al. Correction: Targeting ARHGEF12 promotes neuroblastoma differentiation, MYCN degradation, and reduces tumorigenicity. Cell Oncol (Dordr). 2023.
Cheng Y, Xiao Y, Ruan Y, Wang J, Tian Y, Xiong J, Wang J, Wang F, Zhang C, Xu Y, et al. Corrigendum to "Comparative expression analysis of TEADs and their splice variants in mouse embryonic stem cells" [Gene Expr Patterns 47 (2022) 119302/36516960]. Gene Expr Patterns. 2023;49:119332.
Wu W, Ding S, Mingming Z, Yuping Z, Sun X, Zhao Z, Yang Y, Hu Y, Dong H. Cost effectiveness analysis of CAR-T cell therapy for patients with relapsed/refractory multiple myeloma in China. J Med Econ. 2023:1-15.
Sharma A, Boelens J-J, Cancio M, Hankins JS, Bhad P, Azizy M, Lewandowski A, Zhao X, Chitnis S, Peddinti R, et al. CRISPR-Cas9 Editing of the and Promoters to Treat Sickle Cell Disease. N Engl J Med. 2023;389(9):820-832.
Yang Y, Kang X, Hu S, Chen B, Xie Y, Song B, Zhang Q, Wu H, Ou Z, Xian Y, et al. CRISPR/Cas9 mediated β-globin gene knockout in rabbits recapitulates human β-thalassemia. J Biol Chem. 2021:100464.

Pages